Peste des petits ruminants and cystic hydatidosis may be simultaneously endemic in a given area. Their pathogens are small ruminant morbillivirus (SRMV) and Echinococcus granulosus (E. granulosus), respectively. The SRMV, formerly called peste-des-petits-ruminants virus (PPRV), is classified into the genus Morbillivirus in the family Paramyxoviridae. This virus is an ideal vaccine vector to deliver immunogenic proteins. In this study, a reverse genetics system was developed to rescue a recombinant SRMV (Nigeria 75/1 strain) expressing E. granulosus EG95 antigen in vitro. The recombinant SRMV, albeit replicating more slowly than its parental virus, could effectively express the EG95 antigen in cells by analyses of Western blot, indirect immunofluorescence and mass spectrometry. An EG95 subunit vaccine has been widely used for prevention of cystic hydatidosis in some areas of China. The EG95-expressing SRMV, if proven to induce effective immune responses against both diseases in a future animal experiment, would become a potential candidate of bivalent vaccine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.virusres.2018.12.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Ferritin-Based Eg95 Nanoparticle Vaccine Adjuvanted with pCpG Eliciting Robust Immune Responses Against Cystic Echinococcosis in Mice Model.
Int J Nanomedicine
January 2025
Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing, People's Republic of China.
Introduction: Cystic echinococcosis (CE), a chronic disabling parasitic zoonosis, poses a great threat to public health and livestock production and causes huge economic losses globally. The commercial Quil-A-adjuvanted Eg95 vaccine was empirically effective for CE control; however, it is expensive and has side effects and insufficient immunity.
Purpose: This study aimed to employ a novel adjuvant consisting of a delivery system and an immune potentiator and assess its adjuvanticity to Eg95 antigen, thereby developing a safe and cost-effective novel vaccine against the disease.
Expression and serodiagnostic efficacy of a novel echinococcosis-specific recombinant fusion antigen rAgB8/1-Em18-Eg95.
Parasitology
December 2024
Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China.
Echinococcosis lacks sensitive serological diagnostic tools. The echinococcosis-specific antigens Eg95, AgB8/1 and the Em18 gene sequences were fused and expressed as the novel recombinant antigens rAgB8/1-Em18-Eg95 (T3) and rEm18-Eg95 (T2), used for the diagnosis of hydatid disease, prepared into an enzyme-linked immunosorbent reaction (ELISA) kit, and evaluated for their serological diagnostic value. The relative molecular weight of the T3 protein was 88.
View Article and Find Full Text PDF[Construction, Identification, and Expression of -Based Recombinant Vaccine for ].
Sichuan Da Xue Xue Bao Yi Xue Ban
November 2023
（ 400016） Institute of Infections and Parasitic Diseases, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Article Synopsis
- The study aimed to create a recombinant vaccine (rLL-Eg95) for the disease caused by the parasite Echinococcus granulosus (Eg), focusing on how effectively the vaccine's components were expressed.
- The construction involved obtaining the 95 gene through PCR, then inserting it into a plasmid, which was transformed into bacterial cells to produce the recombinant vaccine, with validation by restriction enzyme digestion and PCR.
- Results confirmed the presence of the expected gene segment and the successful expression of the Eg95 protein, indicating the vaccine is promising due to its ability to evoke an immune response in infected mice.
A DNA vaccine (EG95-PT1/2/3-IL2) encoding multi-epitope antigen and IL-2 provokes efficient and long-term immunity to echinococcosis.
J Control Release
September 2023
National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu 610041, China. Electronic address:
Echinococcosis is a highly prevalent global zoonosis, and vaccines are required. The commercial vaccine based on a protein-based subunit (EG95), however, is limited by its insufficient cellular immunity, a short protection period, and limited prevention against novel mutant strains. Herein, we applied bioinformatics to develop a DNA vaccine (pEG95-IL2) expressing both multi-epitope-based antigens (EG95-PT1/2/3) and an IL-2 adjuvant to regulate T cell differentiation and memory cell response.
View Article and Find Full Text PDFProtection against cystic echinococcosis in sheep using an -expressed recombinant antigen (EG95) as a bacterin.
Parasitology
January 2023
Faculty of Veterinary and Agricultural Sciences, Melbourne Veterinary School, University of Melbourne, Werribee, Victoria 3030, Australia.
The EG95 recombinant vaccine is protective against cystic echinococcus in animal intermediate hosts. Preparation of the existing, registered EG95 vaccines involves semi-purification of the vaccine protein, adding to the cost of production. Truncation of the EG95 cDNA, shortening both the amino and carboxy-termini of the protein, leads to high levels of recombinant protein expression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!